Work

Metabolic transport blockade enhances chimeric antigen receptors T cell therapy against B cell lymphoma

Year: 2024
Type: dissertation
Abstract: Chimeric antigen receptor (CAR) T cells have shown remarkable results against B cell malignancies, but only a minority of patients have long-term remission. The metabolic requirements of both tumour cells and activated T cells result in production of lactate and depletion of key nutrients fundamental for T cell function, like glucose and glutamine. Here, we studied the combination of CD19-specific CAR T cell therapy with pharmacological blockade of metabolic transporters against B cell lymphoma. \nThe export of lactate is facilitated by expression of monocarboxylate transporters (MCTs). CAR T cells express high levels of MCT-1 and MCT-4 upon activation, while certain tumours predominantly express MCT-1. MCT-1 inhibition with the small molecules AZD3965 or AR-C155858 induced CAR T cell metabolic rewiring, but their effector function and phenotype remained unchanged, suggesting CAR T cells are insensitive to MCT-1 inhibition. Moreover, improved cytotoxicity in vitro and antitumoral control on mouse models was found with the combination of CAR T cells and MCT-1 blockade. \nTumour and CAR T cells express high levels of the glutamine transporter ASCT-2 to sustain energy and biomass production. Pharmacological inhibition of ASCT-2 with V-9302 severely suppressed CAR T cell functions and expression of surrogate glutamine transporters like ATB0+, partially restored CAR T cell proliferation. However, glutamine-neutralizing antibodies against ASCT-2 showed limited efficacy against tumour and CAR T cells. \nThis work highlights the potential of selective targeting metabolism via inhibition of metabolic transporters in combination with CAR T cells therapies against B cell malignancies.
Author: López Cabrera, Ernesto
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: green
OpenAlex ID: W7011503031
Cites: 344
Cited by:
Related to: 10